BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8590846)

  • 21. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma.
    Yoshida T; Nakamura S; Ohtake S; Okafuji K; Kobayashi K; Kondo K; Kanno M; Matano S; Matsuda T; Kanai M
    Cancer; 1990 Nov; 66(9):1904-9. PubMed ID: 1699654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
    Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
    Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
    Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
    J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
    Hovgaard D; Nissen NI
    Leuk Lymphoma; 1992 Jun; 7(3):217-24. PubMed ID: 1477649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
    Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
    J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.
    Hovgaard DJ; Nissen NI
    J Clin Oncol; 1992 Mar; 10(3):390-7. PubMed ID: 1740678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of recombinant human granulocyte colony-stimulating factor administration in normal and experimentally infected newborn rats.
    Iguchi K; Inoue S; Kumar A
    Exp Hematol; 1991 Jun; 19(5):352-8. PubMed ID: 1709109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN
    Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
    Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
    Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
    J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.